2Cooper ME. Pathogenesis, prevention, and treatment of diabetic neophropathy[J]. Lancet,1998,352 (9123) :213- 219.
3Brenner BM,Cooper ME,Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J], N Eng J Med, 2001,345 (12) : 861-869.
4George B, Ellen B, Matthew W, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy[J]. Kidney Int, 2008,74 (3) : 364-369.
6Dobrzynski E, Yoshida H, Chao J, et al. Adenovirus-mediated kallikreingene gene delivery attenuates hypertension and protects against renal in jury indeoxycorticosterone-salt rats [J].Immunopharmacology, 1999,44(12):57-65.
7Pickup JC, Crook MA. Is type 2 diabetes mellitus a disease of the innate immune system [J]? Diabetologia, 1998, 41 (10):1241-1248.
8Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature[J]. Cire Res, 1999,85(8):753- 766.
9Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6 and risk of developing type 2 diabetes mellitus [J]. JAMA,2001,286(3):327-334.
10Tsirpanlis G, Chatzipanagiotou S, Nicolaou C, et al. Microinflammation versus inflammation in chronic renal failure patients [ J ]. Kidney Int, 2004,66(12):2093- 2098.
